Author

F. Şirvan

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

Thymic carcinoma (TC) is a rare and aggressive malignancy with limited evidence guiding second-line treatment after prior systemic therapy. We evaluated real-world outcomes of second-line systemic therapy in a multicenter cohort. Adults with unresectable, recurrent, or metastatic TC who received second-lin...

Fatih Kuş, Fatih Atalah, Gökhan Şahin et al. · BMC Cancer · 0 citations

Open access Sep 2026

Real-world outcomes of first-line carboplatin–etoposide–atezolizumab in extensive-stage small-cell lung cancer

Aim: The addition of atezolizumab to platinum-etoposide chemotherapy has become the standard first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, real-world data regarding treatment outcomes and prognostic factors remain limited. This study evaluated the effectiveness of first-line carbop...

A. Koçanoğlu, O. Ünsal, Ibrahim Karadag et al. · Ege Tıp Dergisi · 0 citations